Research programme: serotonin 1F receptor agonists - Eli Lilly/Lundbeck

Drug Profile

Research programme: serotonin 1F receptor agonists - Eli Lilly/Lundbeck

Alternative Names: LY 418094

Latest Information Update: 02 Mar 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly; Lundbeck Research USA
  • Class
  • Mechanism of Action Serotonin 1F receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 01 Mar 2017 CoLucid Pharmaceuticals has been acquired by Eli Lilly
  • 22 Feb 2006 No development reported - Preclinical for Migraine in USA (unspecified route)
  • 17 Mar 2003 Synaptic Pharmaceutical has been acquired by Lundbeck A/S
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top